IPM Take
Magnesium rarely gets the attention given to troponin, potassium or creatinine in emergency medicine.
That may need to change.
A new analysis of more than 1.2 million adults presenting to emergency departments found hypomagnesemia in roughly one in eight patients with a recorded magnesium result. Even after matching patients for demographics and major comorbidities, low magnesium remained associated with substantially higher short-term mortality and more cardiac arrhythmias.
The headline number sounds dramatic: an odds ratio of 1.72 for 30-day mortality.
But the absolute difference matters too.
Thirty-day mortality was 3.24% among patients with hypomagnesemia compared with 1.91% among matched patients with magnesium in the normal range, an absolute difference of 1.33 percentage points.
That is clinically meaningful at emergency-department scale.
It is not proof that magnesium deficiency itself caused those deaths.
Low magnesium may partly be a marker of acute illness, malnutrition, gastrointestinal loss, medication use, kidney dysfunction or broader physiological instability. Propensity matching can reduce measured differences between groups, but it cannot remove every source of confounding.
The policy question is therefore not whether every low magnesium result should trigger aggressive replacement.
It is whether an inexpensive, routinely available laboratory measure could be used more intelligently as part of emergency risk stratification, particularly when it appears alongside QT prolongation, ventricular arrhythmia, hypokalemia or other signs of electrical instability.
Magnesium may be a “forgotten cation.”
But turning it into a useful clinical signal will require more than remembering to order the test.
Executive Summary
Researchers used the TriNetX Research Network to analyse 1,246,550 adults who attended an emergency department during 2025 and had serum magnesium measured.
Hypomagnesemia, defined as a magnesium concentration of 1.6 mg/dL or lower, was identified in 164,663 patients, or 13.2% of the cohort.
The researchers divided deficiency into three categories:
- mild: 1.3 to 1.6 mg/dL
- moderate: 1.0 to 1.2 mg/dL
- severe: below 1.0 mg/dL
After 1:1 propensity score matching for demographic characteristics and comorbidities, 30-day mortality was 3.24% among patients with hypomagnesemia compared with 1.91% among controls with normal magnesium.
The corresponding odds ratio was 1.72.
Seven-day mortality was also higher, at 1.23% versus 0.76%.
Arrhythmias within 30 days occurred in 1.58% of patients with hypomagnesemia compared with 1.12% of matched controls, and arrhythmia rates increased as magnesium deficiency became more severe.
The outcomes included clinically important rhythm abnormalities such as torsades de pointes, ventricular tachycardia, ventricular fibrillation, sudden cardiac arrest and QT prolongation.
The study is large and clinically relevant, but observational.
It cannot establish that magnesium replacement would reduce mortality, nor does it show that routine magnesium testing in every emergency patient improves outcomes.
Why it matters
- HTA bodies: Serum magnesium testing is inexpensive and already widely available, but widespread testing or protocolised replacement should still be judged by whether it changes management and improves outcomes. Association with mortality alone is not enough to establish the value of universal screening.
- → Payers: The study raises the possibility that a low-cost laboratory marker could identify patients needing closer monitoring before more expensive complications occur. But economic value would depend on whether testing and targeted intervention reduce arrhythmias, admissions or mortality rather than simply increase laboratory utilisation.
- → Industry / innovation partners: Risk-stratification tools increasingly combine routine laboratory results with ECG and electronic health-record data. Magnesium could become one of several variables incorporated into decision-support algorithms, but prospective validation would be necessary before automated escalation pathways are justified.
Magnesium is rarely the laboratory result that dominates an emergency department handover. Troponin can suggest myocardial injury, potassium can immediately raise concern about electrical instability, and creatinine can alter treatment decisions within minutes. Magnesium often sits further down the list.
A study of more than 1.2 million emergency department patients suggests that it may deserve more attention.
Researchers analysing electronic health records from the TriNetX network found that 13.2% of adults who had their magnesium measured were hypomagnesemic, defined as a serum magnesium concentration of 1.6 mg/dL or lower. More importantly, those patients were substantially more likely to die within the following month.
Before adjustment, 30-day mortality was 3.8% among patients with low magnesium compared with 2.0% among those whose levels were within the normal range. Even after the researchers matched patients for age, sex, race, ethnicity and major comorbidities, the difference remained: 3.24% versus 1.91%.
The association extended beyond mortality. Patients with hypomagnesemia also had more cardiac arrhythmias, and the frequency increased as magnesium deficiency became more severe.
That gives the finding an obvious cardiovascular dimension. Magnesium helps regulate myocardial electrical activity, and severe deficiency has long been associated with QT prolongation and potentially dangerous ventricular arrhythmias, including torsades de pointes. In emergency medicine, correcting significant magnesium deficiency is therefore hardly a novel concept.
What is new is the scale of the signal.
A common abnormality with a difficult interpretation
The temptation is to read the study as evidence that low magnesium itself is driving mortality.
The data cannot establish that.
Hypomagnesemia can accompany a long list of clinical problems, including gastrointestinal losses, poor nutritional intake, medication use, uncontrolled diabetes and renal magnesium wasting. In an acutely ill patient, it may therefore be less a single cause of deterioration than a marker that several physiological systems are already under strain.
That distinction matters.
A patient with vomiting, dehydration and a mildly reduced magnesium level is not necessarily in the same clinical situation as someone with severe hypomagnesemia, prolonged QT, hypokalemia and ventricular ectopy. Yet both may enter the same broad laboratory category.
The study’s retrospective design means that unmeasured differences between patients could also have influenced the results. Propensity matching can make two groups more comparable, but it cannot account for every factor that affects mortality. Diet, over-the-counter medication use, socioeconomic circumstances and baseline functional status were among the variables the researchers could not fully capture.
There is another important limitation. The analysis included people who already had magnesium measured in the emergency department. Clinicians do not necessarily order the test randomly. Patients who appeared sicker or had particular medical problems may have been more likely to be tested in the first place.
So the study should not be interpreted as proof that magnesium deficiency caused the excess deaths.
But that does not make the result clinically unimportant.
The value may lie in recognising risk earlier
Emergency medicine already relies on markers that are valuable partly because they identify a patient whose physiology is under stress.
Magnesium could have a similar role.
The question is whether clinicians and health systems are using that information consistently.
A low magnesium level may become particularly meaningful when combined with other findings: hypokalemia, QT prolongation, exposure to QT-prolonging medication, structural heart disease or an existing arrhythmia. In those circumstances, the laboratory result is no longer an isolated number. It becomes part of a pattern of electrical vulnerability.
That creates an opportunity for more structured clinical pathways.
Electronic health records could, for example, flag combinations of severe hypomagnesemia, abnormal potassium and QT prolongation for medication review or closer ECG monitoring. Hospitals could standardise when repeat testing is required and when oral or intravenous replacement is appropriate.
But the study does not justify turning every low result into an automatic admission, telemetry order or intravenous infusion.
The absolute differences remain important. After matching, 30-day mortality increased from 1.91% to 3.24%, while arrhythmias occurred in 1.12% of patients with normal magnesium and 1.58% of those with hypomagnesemia. Those differences matter across large emergency populations, but they also show why clinical context remains essential.
The next question is not whether magnesium matters
Clinicians already know that severe electrolyte disturbances can destabilise the heart.
The more useful question is whether emergency departments can identify the patients in whom correcting magnesium or increasing surveillance actually changes outcomes.
That is where the current evidence becomes much thinner.
The new study shows association, not treatment effect. It does not tell us whether routine magnesium testing across all emergency patients would save lives. It does not show that replacing magnesium in every patient with mild deficiency would reduce mortality. And it does not establish the threshold at which a low value should change disposition or monitoring.
Those are intervention questions, and they require prospective studies.
That evidence would be particularly valuable because magnesium has several characteristics that make it attractive from a health-system perspective. The test is inexpensive. Replacement is widely available. The biology linking severe deficiency with arrhythmia is well established. And the abnormality appears common enough that even a relatively small improvement in outcomes could have consequences at population scale.
But inexpensive interventions are not automatically cost-effective interventions. When a test or treatment is applied to millions of people, small increases in laboratory use, monitoring and hospital observation can translate into substantial expenditure.
The policy case therefore depends on identifying where magnesium testing actually changes care.
From the “forgotten cation” to a useful clinical signal
The authors describe magnesium as the “forgotten cation”, a phrase that captures its unusual position in acute medicine.
It is familiar enough that nobody considers it exotic, yet often peripheral enough that a mildly abnormal value may receive little attention once more urgent problems have been addressed.
This study makes that approach harder to defend entirely.
Low magnesium was common. It was associated with higher short-term mortality. It tracked with more arrhythmias. And the risk increased as deficiency became more severe.
What it does not tell clinicians is exactly what to do with that information.
That is now the more interesting question.
The next generation of research should move beyond asking whether hypomagnesemia identifies higher-risk patients and test whether structured responses to that finding improve outcomes. That could mean targeted replacement, medication review, repeat laboratory testing, ECG surveillance or combinations of those interventions in clearly defined high-risk groups.
Until then, magnesium should probably be neither ignored nor overinterpreted.
The important shift is smaller but meaningful: a low magnesium result may deserve to be read as part of the patient’s cardiovascular risk picture, rather than as an isolated laboratory abnormality waiting quietly to be corrected.
